Lantheus Holdings, Inc. and Ligand Pharmaceuticals Incorporated: A Detailed Gross Profit Analysis

Explore the financial journey of two pharma giants.

__timestampLantheus Holdings, Inc.Ligand Pharmaceuticals Incorporated
Wednesday, January 1, 201412551900055402000
Thursday, January 1, 201513552200066107000
Friday, January 1, 2016137780000103402000
Sunday, January 1, 2017162135000135736000
Monday, January 1, 2018174885000245116000
Tuesday, January 1, 2019174811000108935000
Wednesday, January 1, 2020138761000156000000
Friday, January 1, 2021187695000214957000
Saturday, January 1, 2022581703000143418000
Sunday, January 1, 202370954300096265000
Loading chart...

In pursuit of knowledge

A Comparative Analysis of Gross Profit Trends

In the competitive landscape of the pharmaceutical industry, understanding financial performance is crucial. This analysis delves into the gross profit trends of Lantheus Holdings, Inc. and Ligand Pharmaceuticals Incorporated from 2014 to 2023. Over this period, Lantheus Holdings has demonstrated a remarkable growth trajectory, with its gross profit increasing by approximately 465%, peaking in 2023. In contrast, Ligand Pharmaceuticals experienced a more volatile journey, with a notable peak in 2018, followed by fluctuations, ultimately leading to a 61% decrease by 2023. This divergence highlights Lantheus Holdings' strategic advancements and market adaptability, while Ligand Pharmaceuticals faces challenges in maintaining consistent growth. Such insights are invaluable for investors and stakeholders aiming to make informed decisions in the ever-evolving pharmaceutical sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025